CSL may have been sitting on a treatment that opens the door to a $33.6billion cholesterol-lowering drugs market

CSL may have been sitting on a treatment that opens the door to a $33.6billion cholesterol-lowering drugs market. The experimental treatment was the focus of three papers presented at the American Heart Association's scientific meeting in Dallas. Instead of discarding unused blood components from making hemophilia, burns and immune-system treatments, it could extract the beneficial cholesterol known as HDL and infuse it into patients. HDL therapy may quell inflamed arteries and dissolve the life-threatening plaques that clog them. CSL's chief scientist, said the treatment was a big focus for the Company. If this works, we could save a lot of lives and it could be very good for the company commercially. If approved the product could attract sales of up to $500 million in the first 5 years. According to UBS analyst, Andrew Goodsall, for a lot of investors, this is a point of excitement. (VIEW LINK)


2 topics

The Livewire Equities feed brings you a range of insights that relate to Australian equities

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.